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ABSTRACT 
 
Background: The development of cervical cancer is highly dependent on the 
ability of cancer cells to form new capillaries and lymphatic vessels. Neo-adjuvant 
chemotherapy shrinks tumor size and reduces angiogenesis. Of the various growth 
factors that regulate angiogenesis, VEGF-C is the first-rank lymphangiogenic 
factor. VEGF-C can be measured by several methods. This study aimed to 
determine: (1) the effect of neo-adjuvant chemotherapy in reducing tissue VEGF-
C expression and serum VEGF-C level; (2) the correlation between VEGF-C 
expression in tissueand serum VEGF-C in patients with bulky cervical cancer 
receiving paclitaxel – carboplatin neoadjuvan chemotherapy. 
Subjects and Method: This was a quasi experiment conducted at the 
Obstetrics and Gynecology Department and the Pathology and Anatomy 
Department, Dr. Moewardi Hospital, Surakarta, Central Java, from May to 
September 2017. A sample of 30 patients with cervical cancer stage IB2 and IIA2 
was selected for this study. The independent variable was paclitaxel – carboplatin 
neoadjuvan chemotherapy. The dependent variables were VEGF-C expression in 
tissue and VEGF-C serum. Tissue VEGF-C expression and serum VEGF-C level 
were measured before and after neo-adjuvant chemotherapy. The data were 
analyzed by Wilcoxon test and Spearman correlation. 
Results: TissueVEGF-C expression before chemotherapy (mean= 6.17) was 
higher than after therapy (mean= 4.17), and it was statistically significant (p< 
0.001). Serum VEGF-C level before chemotherapy (mean= 9574.60) was higher 
than after therapy (mean= 7827.63), and it was statistically significant (p= 
0.006). Tissue VEGF-C expression was correlated with serum VEGF-C, but it was 
statistically non-significant (r= 0.15, p= 0.218). 
Conclusion: Neo-adjuvant chemotherapy reduces both VEGF-C tissue 
expression and serum VEGF-C levels. There is a weak and insignificant 
correlation between tissue VEGF-C expression and serum VEGF-C levels in 
patients with cervical cancer given neo-adjuvant chemotherapy.  
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